Going atom-by-atom, Stanford researchers craft a new precision drug for fighting COVID-19
The rapidly evolving SARS-CoV-2 virus threatens the progress made in curbing the COVID-19 pandemic. Stanford Bio-X affiliated faculty member Michael Lin and Novo Nordisk Foundation-sponsored Stanford Bio-X Visiting Scholar Michael Westberg have developed a promising novel drug candidate, designed at the atomic level, that could help doctors halt the rise of lethal new drug resistant variants. Co-authors include Stanford Bio-X affiliated faculty members Shirit Einav and Catherine Blish and Stanford Bio-X Fellows Xinzhi Zou and Yan Wu.